scholarly journals Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

2022 ◽  
Author(s):  
Fredrik H Schjesvold ◽  
Meletios-Athanasios Dimopoulos ◽  
Sosana Delimpasi ◽  
Pawel Robak ◽  
Daniel Coriu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase

scholarly journals Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

The Lancet ◽  
2020 ◽  
Vol 396 (10262) ◽  
pp. 1563-1573
Author(s):  
Sebastian Grosicki ◽  
Maryana Simonova ◽  
Ivan Spicka ◽  
Ludek Pour ◽  
Iryrna Kriachok ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase

Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS8062-TPS8062 ◽  
Author(s):  
S.Vincent Rajkumar ◽  
Peter Michael Voorhees ◽  
Hartmut Goldschmidt ◽  
Ross I. Baker ◽  
Rajesh Bandekar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Open Label ◽  
Phase 3 ◽  
Active Monitoring ◽  
Smoldering Multiple Myeloma ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document